Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose.
about
Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in TanzaniaPopulation pharmacokinetics of meropenem during continuous infusion in surgical ICU patients.Modeling and simulation of count data.New generalized poisson mixture model for bimodal count data with drug effect: An application to rodent brief-access taste aversion experiments.Calculation of a First-In-Man Dose of 7-O-Succinyl Macrolactin A Based on Allometric Scaling of Data from Mice, Rats, and Dogs.Age, Weight, and CYP2D6 Genotype Are Major Determinants of Primaquine Pharmacokinetics in African Children.Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure-Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism.A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer PatientsImpact of the superoxide dismutase 2 Val16Ala polymorphism on the relationship between valproic acid exposure and elevation of γ-glutamyltransferase in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis.Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic AmyloidosisA pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patientsDetermination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis.Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients.Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescentsColistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.Population pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism--the Hokusai-VTE phase 3 studyPharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing.Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic ExtractionInvestigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach.Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa.A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro.Clindamycin Pharmacokinetics and Safety in Preterm and Term InfantsApplication of the Multistate Tuberculosis Pharmacometric Model in Patients With Rifampicin-Treated Pulmonary TuberculosisMorbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen.The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African childrenPopulation pharmacokinetic modeling of cefadroxil renal transport in wild-type and Pept2 knockout miceA Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients.Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.Mechanism-Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake.Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin.Application of a systems pharmacology model for translational prediction of hERG-mediated QTc prolongation.A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.The multistate tuberculosis pharmacometric model: a semi-mechanistic pharmacokinetic-pharmacodynamic model for studying drug effects in an acute tuberculosis mouse model.Pharmacometrics and Systems Pharmacology Software Tutorials and Use: Comments and Guidelines for PSP Contributions.Population pharmacometrics in support of analgesics studies.Influence of Morbid Obesity on the Pharmacokinetics of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide.A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients.
P2860
Q28550488-A034A798-D8B3-464E-8054-A9D4DE73873FQ30316322-CFF607C6-F778-4313-BC2F-8063179BEE0CQ30842267-7CC6810B-C884-4E47-AC00-E80C6A08DF72Q31118425-7FFCE278-BA91-4765-8B0B-CD046826F7DDQ31172628-F974EC7E-62DC-4ACE-8186-06B62625AC3CQ33601837-EFF56494-0E70-450D-8735-A406BBB37CB1Q33729811-1FEBC6AF-CAA7-42F2-8311-D3BA4203D72FQ33845632-D2EC0605-E5BA-420D-B56B-AF33EB843E86Q34456179-99A96836-2068-4532-A8C8-3957866F9308Q35168927-4DC64CE0-2F05-47A9-BD7F-58D0EF414764Q35179540-FE5D3D48-CB39-45C1-99DB-3F72D2530D09Q35193385-80AC15AC-0BF0-409A-9A1C-408D2B820A02Q35814413-C820D72E-20D4-4815-A707-A2429978783CQ36158212-5505AAD5-0F93-4C90-A939-ABA3310C9A76Q36232524-3EAED3AA-0217-4CB6-9C9D-E7E5404D119AQ36243689-03FDD895-0911-4CC1-A7DE-558DD6A5BC8FQ36290841-5C12A218-F01E-4242-9A47-CAEF91442D1EQ36410089-72C02D31-BB3F-4FAC-9CC7-942D2B3887E0Q36410129-CA30B5F8-E30C-4C6E-B87B-81FB3E5481D2Q36438900-51A8AE30-7FAD-4EFF-92C0-E961C7985744Q36618141-BF92A5C9-1B2A-4659-AF08-060E6DBAD3A5Q36644907-2177836D-B1AE-4E55-9887-E16A26BD1966Q36684146-9C74A364-DA08-422B-A314-4483717B9DF8Q36887756-998F6FE0-33C8-403E-AB69-9400770B0668Q36918510-C45D5686-CED2-4EA5-9D3E-2B86194C2D9DQ37026910-E2227D49-2AD7-441B-A903-76AF992F28E4Q37030715-3E86036F-D777-40CE-87DA-C9633FA6BAA6Q37093326-87C8F102-3A06-4057-8B5B-3E701D98C8A7Q37348405-873BD81F-4B66-4428-A142-144A10587D0BQ37509532-FB539EE0-1F28-4C5C-9C8F-A2C57E8E8C48Q37538760-BDE669D0-8584-46F5-B819-00DE50FA6340Q37540015-671C8C3A-EC3F-4A70-8CDF-16566AA2EA61Q37540020-3A68395B-7979-46C9-999A-2DB15D786C58Q37579944-1B6907D9-B5A7-4277-850A-4C9679947146Q37733479-DD23ED65-9843-4D43-9BD5-0CB77DA4242DQ37733488-09AF6F43-8E54-41B2-8F11-E03D01ACA155Q38172404-D2FCA287-E5DB-4A72-8649-989B41D64DC1Q38175171-F38681AE-78D2-44C9-B7F4-45D8D9AE0D8BQ38376713-09798045-3A97-4EAE-8D34-1D4A0D1A9513Q38378485-AB74BAC3-90FA-40F5-9C8C-941C77F1FEA9
P2860
Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose.
@en
type
label
Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose.
@en
prefLabel
Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose.
@en
P2860
P356
P1476
Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose.
@en
P2093
M O Karlsson
R J Keizer
P2860
P356
10.1038/PSP.2013.24
P577
2013-06-26T00:00:00Z